TPST-2003 delivered a 100% complete response rate among the six efficacy-evaluable patients in the ongoing REDEEM-1 Phase 1/2a trial, with a 100% overall response rate across 25 evaluable patients pooled from REDEEM-1 and a prior investigator-initiated study. No Grade ≥3 CRS or ICANS were reported in REDEEM-1; one patient at the highest dose experienced low-grade ICANS. In the earlier IIT, median PFS reached 23.1 months, including in patients with extramedullary disease, and all evaluable patients remained MRD-negative at 12 months.
The core development: Tempest released interim China-generated data for TPST-2003, an autologous CD19/BCMA dual-targeting CAR-T for relapsed/refractory multiple myeloma, and outlined plans to file a U.S. IND and, pending clearance, initiate a U.S. registrational study in 2026. The program is being conducted by partner Novatim Immune Therapeutics in China, with Tempest retaining rights outside China, India, Turkey, and Russia. To date, 36 patients have received a single infusion across the two studies, including 12 in REDEEM-1, where participants had a median of four prior lines. The construct’s parallel dual-targeting design aims to blunt antigen escape and address tumor heterogeneity, with consistent responses observed across dose levels and study settings in the data disclosed.
Strategically, Tempest is moving to convert an emerging China clinical signal into a rapid U.S. path, leaning on a dual-target architecture to differentiate against approved BCMA-only products amid persistent relapse and durability concerns. The approach aligns with a broader trend toward multi-antigen targeting to extend remissions without stacking external combinations that add regulatory and operational load. The tension is whether a small efficacy-evaluable set in REDEEM-1 and IIT-derived durability can credibly anchor a U.S. registrational plan. That will require early FDA dialogue on data portability, assay and endpoint alignment, and CMC comparability if manufacturing shifts from China to U.S. facilities. Tempest’s concurrent platform ambitions—an allogeneic CD19/BCMA and an in vivo CD19/BCMA program—signal a bid to broaden addressable populations and reduce supply constraints, but they also fragment resources and increase regulatory touchpoints.
For sites, the safety profile, if maintained at scale, could ease ICU planning and expand participation beyond high-acuity centers, though the autologous workflow still demands apheresis capacity, slot coordination, and vein-to-vein time management. With established MM CAR-Ts already vying for the same late-line population, enrollment will hinge on site prioritization, real-time manufacturing slot availability, and clear bridging therapy guidance. CROs will face a complex trial operations brief: cross-border data integration, stringent CMC and analytics comparability packages, and potential adaptive designs to accelerate dose selection. Regulators will focus on durability versus cilta-cel benchmarks, consistency in high-risk cytogenetics and extramedullary disease, and whether the dual-target construct alters the safety signature at higher doses or with broader use. Vector suppliers and cell-processing partners will be pivotal to scale, as any release delays could erase operational advantages implied by lower acute toxicity.
The near-term watchlist is straightforward. Tempest needs a larger REDEEM-1 dataset with durable responses beyond six evaluable patients, clarity on dose selection, and a clean safety read at the top dose. FDA feedback on the IND, the acceptability of foreign clinical data to support U.S. development, and manufacturing tech-transfer plans will set the regulatory trajectory. Positioning within the treatment sequence will matter; moving earlier in the algorithm raises the evidentiary bar. Competitive pressure from next-generation bispecifics and emerging allogeneic or in vivo cell therapies will intensify. If Tempest can pair reproducible durability with a scalable CMC package, the program could reshape how dual-target CAR-T is operationalized in myeloma; if not, the plan risks stalling on execution rather than biology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
